Methyl 2-cyanoisonicotinate（CAS# 94413-64-6)
Risk and Safety
| Hazard Class | 6.1 |
Production method
the target compound was prepared by oxidation, amidation and dehydration with methyl 2-methyl 4-pyridinecarboxylate (2) as the starting material. its structure was confirmed by 1H NMR and MS, and the total yield was 53.0%. The effects of feeding ratio, crystallization temperature, reaction time and other factors on the product were studied by single-factor experiments, and the process conditions were optimized: n(2):n (potassium permanganate) = 1.0:2.5, crystallization temperature 0~5 ℃;n (methyl 2-carboxyl -4-pyridinecarboxylate):n (sulfoxide) = 1.0:1.4, reaction; the dehydration reaction selects the trifluoroacetic anhydride-triethylamine system as the dehydrating agent. The process is simple to operate, the reaction conditions are mild, easy to scale up production, and has good practical application value.
Use
Tobisostat is used to treat chronic hyperuricemia of gout. Compared with the traditional drug allopurinol (purine analog), it will not affect purine and pyridine metabolism and enzyme activity, and it reduces uric acid The effect is stronger, no large-dose repeated administration is required, and the safety is better. Methyl 2-cyano-4-pyridine carboxylate is an important raw material for the synthesis of Tobiso.
